Arina A. Ibragimova

Arina A. Ibragimova

Auto-generated profile, based on publicly available information

Arina A. Ibragimova

Tomsk National Research Medical Center, Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2025 in Acta Naturae
Verified
Journal Article
Open access
PDF file
AIArina Ibragimova
Arina Ibragimova
AFAnton Fedorov
Anton Fedorov
KKKirill Kirilenko
Kirill Kirilenko
ECEvgeny L. Choynzonov
Evgeny L. Choynzonov
Evgeny DenisovEvgeny Denisov
Evgeny Denisov
MPMarina Patysheva
Marina Patysheva
MRNA-based cancer vaccines represent an innovative approach to cancer treatment. Cancer mRNA vaccines are structurally based on specific tumor antigens, a technique which enables the patient’s immune system to become activated against cancer cells. Clinical trials of mRNA vaccines against various types of tumors, including melanoma, lung cancer, pancreatic carcinoma, breast cancer and others, are currently underway. Because of their favorable safety profile and adaptability, these therapeutics hold considerable promise in efforts to enhance cancer treatment efficacy and prolong patient life. This review outlines steps in the development of manufacturing technologies for mRNA-based therapeutics, describes the algorithm used to design personalized anti-tumor mRNA vaccines, discusses their practical implementation, and summarizes current clinical trials in cancer immunotherapy.

20 November 2025 in Russian Journal of Oncology
Verified
Journal Article
Closed access
PDF file
TGTatiana Gerashchenko
Tatiana Gerashchenko
PGPolina A. Gervas
Polina A. Gervas
AIArina A. Ibragimova
Arina A. Ibragimova
AZAndrew Sergeevich Zuev
Andrew Sergeevich Zuev
MTMaria S. Tretyakova
Maria S. Tretyakova
ТСТретьякова Мария Сергеевна
Третьякова Мария Сергеевна
A personalized approach is a priority in the diagnosis and treatment of cancer. Accurate diagnostic tests for assessing the tumor’s molecular characteristics and optimizing the treatment strategy are essential for effective personalized treatment. Multigene NGS panels simultaneously detect a variety of genetic disorders, including single nucleotide substitutions, insertions and deletions, DNA copy number variations, translocations, microsatellite instability, and tumor mutational burden. This is crucial for selecting targeted therapy and immunotherapy, assessing prognosis, and monitoring the progression of cancer. This review discusses the evolution of precision oncology in the 21st century, the possibilities and advantages of NGS in molecular oncology, the technical and analytical characteristics of various multigene NGS panels with both amplification-based and hybridization-based enrichment, and their clinical applications in molecular diagnostics. The review focuses specifically on existing Russian and international NGS technologies. It examines available Russian and international multigene NGS panels, including problems of their application in routine cancer care in Russia.